Abstract 99P
Background
Patients with chemotherapy-responsive advanced biliary tract cancer (BTC) are usually observed post 6 months of gemcitabine-based therapy, though most progress within a short time-span and there is limited prospective evidence for maintenance strategies.
Methods
The study is an integrated phase II – III randomised clinical trial (Clinical Trial Registry of India number: CTRI/2017/10/010112) conducted at 2 centres in India. Eligible patients with advanced BTC who had responsive or stable disease status post 6 months of gemcitabine – based chemotherapy were randomly assigned (1:1) to either observation arm (O) or intervention arm (BEER), which was a combination of Bevacizumab 5 mg/m2 IV every 21 days plus erlotinib 100 mg once daily, . Both arms were continued till disease progression, significant toxicity or patients choice. The primary endpoint of the phase II component was progression free survival, measured from randomization into the trial.
Results
Between May 2021 and November 2022, 98 patients (O: 48; BEER: 50) comprising 78 patients with gallbladder cancer (GBC) and 20 patients with cholangiocarcinoma (CC) were randomised with all 98 patients included in the final analysis. With a median follow up of 11.2 months, patients in the BEER cohort showed an improved PFS compared to the observation cohort [5.2 months (95% CI: 3.4-6.9) vs. 3 months (95% CI: 2.5 - 3.5); p=0.004]. The CC cohort tended to derive greater benefit from BEER (6.7 months vs. 2.2 months) than the GBC cohort (4.3 months vs. 3 months). There were no grade 3 or grade 4 adverse events noted, though temporary cessation of erlotinib was required due to grade 2 skin rash in 7 patients (14%), and grade 2 oral stomatitis in 1 patient (2%).
Conclusions
The combination of bevacizumab and erlotinib improves progression free survival in patients with chemotherapy responsive advanced BTC in this phase 2 clinical trial. The ongoing phase III component of the study will evaluate whether the significant benefit in PFS translates to improvement in overall survival.
Clinical trial identification
CTRI/2017/10/010112.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cadilla Pharma Pvt Ltd (supported bevacizumab) Dr. Reddy's Lab pvt Ltd (supported bevacizumab) LUPIN Pharma pvt Ltd Intas pvt Ltd.
Disclosure
A. Ramaswamy: Financial Interests, Institutional, Research Grant: Cipla Health Limited, Dr Reddy Laboratories, Zydus Lifesciences. V.S. Ostwal: Financial Interests, Institutional, Funding, IIS: Cadilla Pharmaceuticals pvt Lts, Reddy's pvt Ltd, Lupin, BDR; Financial Interests, Personal, Invited Speaker, GI ESMO 22: AstraZeneca; Financial Interests, Institutional, Advisory Board: Mankind, Natco. All other authors have declared no conflicts of interest.
Resources from the same session
127P - Prognostic significance of intratumoral and peritumoral budding in distal extrahepatic bile duct carcinoma
Presenter: Sun-Young Jun
Session: Poster session 17
128P - Biliary tract cancers: Epidemiological and prognosis trends of Latin American population
Presenter: Maria del Consuelo Diaz Romero
Session: Poster session 17
129P - Prognostic factors associated with survival in resected biliary tract cancers: A multicentre Italian experience
Presenter: Michele Ghidini
Session: Poster session 17
663P - Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Presenter: Carlos Rojas
Session: Poster session 17
664P - Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
Presenter: Ryan Corcoran
Session: Poster session 17
666P - Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
Presenter: Shun Lu
Session: Poster session 17
667P - Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: David Hong
Session: Poster session 17
668P - Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Alexander Drilon
Session: Poster session 17